Arnon  Rosenthal net worth and biography

Arnon Rosenthal Biography and Net Worth

CEO of Alector
Arnon co-founded Alector in 2013 and has served as a member of our board of directors, as Chief Executive Officer, and as our President since 2013. Arnon co-founded Annexon Biosciences, Inc. and served as its acting Chief Executive Officer from August 2011 to December 2014 and served as a member of the board of directors, including as Chairman from August 2011 to February 2017. Arnon co-founded Rinat Neuroscience Corporation (acquired by Pfizer Inc. in August 2006), and served as President, Chief Scientific Officer and as a member of the board of directors from August 2001 to August 2006. From January 1985 to August 2001, Arnon served in various roles at Genentech, Inc., where he ultimately served as Staff Scientist and was appointed as a permanent member of Genentech’s Research Review Committee, where his team discovered the target for the cancer drug Erivedge. Arnon conducted his post-doctoral fellowship at Genentech, Inc. He holds a Ph.D. in biology from the Hebrew University of Jerusalem.

What is Arnon Rosenthal's net worth?

The estimated net worth of Arnon Rosenthal is at least $12.58 million as of December 4th, 2023. Dr. Rosenthal owns 2,019,217 shares of Alector stock worth more than $12,579,722 as of December 11th. This net worth approximation does not reflect any other assets that Dr. Rosenthal may own. Additionally, Dr. Rosenthal receives a salary of $1,020,000.00 as CEO at Alector. Learn More about Arnon Rosenthal's net worth.

How old is Arnon Rosenthal?

Dr. Rosenthal is currently 67 years old. There are 3 older executives and no younger executives at Alector. Learn More on Arnon Rosenthal's age.

What is Arnon Rosenthal's salary?

As the CEO of Alector, Inc., Dr. Rosenthal earns $1,020,000.00 per year. The highest earning executive at Alector is Dr. Sara Kenkare-Mitra Ph.D., President and Head of Research & Development, who commands a salary of $1,190,000.00 per year. Learn More on Arnon Rosenthal's salary.

How do I contact Arnon Rosenthal?

The corporate mailing address for Dr. Rosenthal and other Alector executives is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. Alector can also be reached via phone at (415) 231-5660 and via email at [email protected]. Learn More on Arnon Rosenthal's contact information.

Has Arnon Rosenthal been buying or selling shares of Alector?

During the past quarter, Arnon Rosenthal has sold $132,500.36 in shares of Alector stock. Most recently, Arnon Rosenthal sold 23,831 shares of the business's stock in a transaction on Monday, December 4th. The shares were sold at an average price of $5.56, for a transaction totalling $132,500.36. Following the completion of the sale, the chief executive officer now directly owns 2,019,217 shares of the company's stock, valued at $11,226,846.52. Learn More on Arnon Rosenthal's trading history.

Who are Alector's active insiders?

Alector's insider roster includes Robert King (Insider), Robert Paul (Insider), Arnon Rosenthal (CEO), Richard Scheller (Director), Shehnaaz Suliman (COO), and Calvin Yu (VP). Learn More on Alector's active insiders.

Are insiders buying or selling shares of Alector?

During the last year, insiders at the sold shares 14 times. They sold a total of 582,376 shares worth more than $3,505,807.83. The most recent insider tranaction occured on December, 4th when CFO Marc Grasso sold 4,574 shares worth more than $25,431.44. Insiders at Alector own 14.0% of the company. Learn More about insider trades at Alector.

Information on this page was last updated on 12/4/2023.

Arnon Rosenthal Insider Trading History at Alector

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/4/2023Sell23,831$5.56$132,500.362,019,217View SEC Filing Icon  
9/5/2023Sell5,647$5.19$29,307.931,645,448View SEC Filing Icon  
6/2/2023Sell5,255$6.90$36,259.501,651,095View SEC Filing Icon  
3/17/2023Sell15,186$6.22$94,456.921,656,350View SEC Filing Icon  
3/2/2023Sell5,849$8.32$48,663.681,628,546View SEC Filing Icon  
11/10/2021Sell55,000$25.00$1,375,000.00View SEC Filing Icon  
11/8/2021Sell100,000$25.00$2,500,000.00View SEC Filing Icon  
11/4/2021Sell100,000$25.00$2,500,000.00View SEC Filing Icon  
9/22/2021Sell100,000$25.33$2,533,000.00View SEC Filing Icon  
9/20/2021Sell100,000$25.80$2,580,000.00View SEC Filing Icon  
See Full Table

Arnon Rosenthal Buying and Selling Activity at Alector

This chart shows Arnon Rosenthal's buying and selling at Alector by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alector Company Overview

Alector logo
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $6.23
Low: $5.97
High: $6.34

50 Day Range

MA: $5.39
Low: $3.77
High: $6.68

2 Week Range

Now: $6.23
Low: $3.66
High: $9.86


617,661 shs

Average Volume

593,478 shs

Market Capitalization

$524.17 million

P/E Ratio


Dividend Yield